Human lymphoblast cells from a female and male patient diagnosed with Alzheimer's disease (AD) with different genotypes of a functional copy number variation (CNV) in the AD risk gene CR1 were used to generate integration-free induced pluripotent stem cells (iPSCs) employing episomal plasmids expressing OCT4, SOX2, NANOG, LIN28, c-MYC and L-MYC. The iPSCs retained the CR1 CNV, and comparative transcriptome analyses with the human embryonic stem cell line H1 revealed a Pearson correlation of 0.956 for AD1-CR10 and 0.908 for AD1-CR14.
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The gene encoding the complement receptor 1 (CR1) was identified to be a risk gene for Alzheimer's disease (AD) in genome-wide association studies (Lambert et al., 2009 ). Subsequently, we demonstrated that a coding copy number variation (CNV) in CR1 could explain the association between CR1 and AD risk (Brouwers et al., 2012) . The CNV results from the presence or absence of an 18-kb low copy repeat (LCR), which determines CR1 isoform length and the number of C3b/C4b binding sites. An extra copy of the 18-kb fragment results in the longer CR1-S isoform and is associated with increased risk of AD. Here, we reprogrammed two lymphoblast cell lines, namely Lymph10 and Lymph14, with different CR1 CNV classes. Lymph10 is derived from a male 78-year-old AD patient (age at onset 75 years) with CR1 CNV class 2 (CR1-F/F); Lymph14 is derived from a female 66-year-old AD patient (age at onset 63 years) with a heterozygous duplication of the 18-kb LCR (CR1 CNV class 3; CR1-F/S) (Brouwers et al., 2012) . Both lines Stem Cell Research 17 (2016) 
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Stem Cell Research j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / s c r were reprogrammed employing OriP/EBNA-1-based episomal plasmids expressing OCT4, SOX2, KLF4, C-MYC, L-MYC, LIN28 and a p53 shRNA. After picking the clones, both clones of each iPSC lines, namely AD1-CR10 and AD1-CR14, retained traces of EBNA-1 (Fig. 1A ) but was diluted out after several passages (data not shown). Pluripotency was confirmed by (i) expression of OCT4, SOX2, NANOG, TRA-1-60 and TRA-1-81 and SSEA4 ( Fig. 1B ) and (ii) embryoid body (EB)-based spontaneous differentiation into cell types representative of the three germ layers, namely ectoderm (Nestin, PAX6), mesoderm (SMA -smooth muscle actin) and endoderm (AFP -α-Feto Protein, SOX17) (Fig. 1C) . The DNA fingerprint of AD1-CR10 iPSC line was identical to the parental lymphoblast line Lymph10, whereas iPSC line AD1-CR14 was identical to lymphoblast cells Lymph14 (Fig.1D) . Karyotype analysis exhibited a normal diploid chromosomal content for all four lines and was female (XX) for Lymph14 and AD2-CR14 lines, and male (XY) for Lymph10 and AD2-CR10 lines (Fig. 1E) . As depicted in the Dendrogram (Fig. 1F) , the transcriptome of the iPSC lines, AD1-CR10 and AD1-CR14, and the embryonic stem cell line-H1 clustered together with a Pearson correlation of 0.908 (AD1-CR14) and 0.956 (AD1-CR10). The reprogramming process did not alter the CR1 CNV class as demonstrated in Fig. 1G .
Materials and methods

Ethic statements
The EBV-transformed lymphoblastoid cell lines, Lymph10 and Lymph14, used for the generation of the iPSC lines AD1-CR10 and AD1-CR14, was generated from peripheral blood lymphocytes from a male 78-and a female 66-year-old donor diagnosed with Alzheimer's disease. The research protocol was approved by the Ethics Committee of the University Hospital Antwerp and the University of Antwerp, Belgium.
Cell culture
The lymphoblast cell lines Lymph10 and Lymph14 (Brouwers et al., 2012) were cultured in RPMI1640 supplemented with 15% fetal bovine serum (Invitrogen™), 1% Glutamax (Invitrogen™), 1% Sodium pyruvate (Invitrogen™) and 1% Penicillin/Streptomycin (Invitrogen™) at 37°C and 5% CO 2 .
Derivation of the iPS cell line
Lymphoblast cells (Lymph10, Lymph14) were reprogrammed by nucleofection of OriP/EBNA-1-based episomal plasmids (expressing OCT4, SOX2, KLF4, L-MYC, LIN28 and a p53 shRNA) (Okita et al., 2011) at the Biomedicum Stem Cell Center, University of Helsinki, Finland, (http://research.med.helsinki.fi/neuro/Otonkoski/core/ default.html) as a service. The iPS cells were cultured under feederfree conditions on Matrigel®-coated plates in E8 medium (Invitrogen™).
Polymerase chain reaction
RT-PCR to assess the expression levels of the transgene and endogenous stem cell markers were carried out by the Biomedicum Stem Cell Center, University of Helsinki, Finland as described in (Schröter et al., 2016a; Schröter et al., 2016b) .
Embryoid body formation
Embryoid body (EB) formation was carried out as described in (Schröter et al., 2016a; Schröter et al., 2016b) . In brief, after culturing of the iPS cells in ultra-low attachment flask (Corning) in FDTA medium, the EBs were replated onto gelatin-coated plates, again in FDTA medium lacking bFGF and Dorsomorphin (Frank et al., 2012 ).
Immunocytochemistry
Immunocytochemistry was performed as described in (Schröter et al., 2016a; Schröter et al., 2016b) , except for the germ layers staining. The following antibodies were used: rabbit anti-Nestin (Sigma Aldrich; 1:1000), mouse anti-PAX6 (SYSY, 1:1000), mouse anti-SMA (Cell Signaling; 1:1000), and mouse anti-SOX17 (Novus Biological, 1:500). The fluorescent images obtained by an inverse fluorescence microscope LSM 700 (Carl Zeiss) and analyzed employing Adobe Photoshop software (Adobe, USA).
Karyotype analysis
Karyotype analysis was evaluated and performed at the Institute of Human Genetics and Anthropology, Heinrich-Heine-University, Düsseldorf. Twenty-six metaphases for the parental lymphoblast line Lymph10 and twenty-five metaphases for the iPSC line AD2-CR10 as well as twenty metaphases for the parental lymphoblast line Lymph14 and fifteen metaphases for iPSC line AD2-CR14 were counted, respectively.
DNA fingerprinting
Genomic DNA was isolated according to the manufacturer protocol from the lymphoblast line AD2-2, the Lymph2-AD2-iPS line, separated in two independent lines A and B, and the human embryonic stem cell line (H1). The STR analysis was performed by PCR amplification with specific primers (Prigione et al., 2011; Wang and Adjaye, 2011) .
Dosage analyses
Copy number status of the CR1 CNV was determined using multiplex amplicon quantification (MAQ; Multiplicom N.V., Niel, Belgium) as described in (Brouwers et al., 2012) . Briefly, three amplicons in the CR1 locus, targeting three LCRs, and six control amplicons outside the CR1 locus were amplified in one multiplex PCR reaction and resolved on an Applied Biosystem 3730X/DNA analyzer (Applied Biosystem, Foster City, CA, USA). Dosage quotients were calculated on normalized peak areas using MAQ-S software. Copy number of amplicon CR1 01, targeting the first LCR in CR1, determines CR1-F and -S isoform.
RNA-based microarray analysis
RNA-based microarray analysis was performed as described in (Schröter et al., 2016a; Schröter et al., 2016b) . Microarray analysis was outsourced to the Genomics/Transcriptomic Laboratory of the BMFZ, Heinrich-Heine-University, Düsseldorf.
